TRIP12 is an ubiquitin ligase for ARF, which is reported to suppress cell growth by activating p53 [25], and frequently harbors inactivating somatic point mutations (100 of 380 (26%) somatic mutations are inactivating [26, 27]) in diverse cancer types. Here, CDKN2A is linked to cancer.